default author photo

Takashi Inozume

Chiba Cancer Center - Research Institute

Japan

  • Chiba Cancer Center - Research Institute

SCHOLARLY PAPERS

2

DOWNLOADS

139

TOTAL CITATIONS

1

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Efficacy Comparison between Anti-PD-1 Antibody Monotherapy and Anti-PD-1 Plus Anti-CTLA-4 Combination Therapy as First-Line Immunotherapy for Advanced Acral Melanoma: A Retrospective, Multicenter Study of 254 Japanese Patients

Number of pages: 29 Posted: 22 Apr 2022
Yasuhiro Nakamura, Kenjiro Namikawa, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Shusuke Yoshikawa, Takeo Maekawa, Shigeto Matsushita, Tatsuya Takenouchi, Takashi Inozume, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Atsushi Otsuka, Noriki Fujimoto, Taiki Isei, Natsuki Baba, Taisuke Matsuya, Ryo Tanaka, Takahide Kaneko, Masazumi Onishi, Yutaka Kuwatsuka, Kotaro Nagase, Takehiro Ohnuma, Motoo Nomura, Yoshiyasu Umeda and Naoya Yamazaki
Saitama Medical University International Medical Center (SIMC) - Department of Skin Oncology/Dermatology, National Cancer Center Hospital, Shinshu University - Department of Dermatology, Nagoya City University, affiliation not provided to SSRN, Shizuoka Cancer Center, Jichi Medical University, affiliation not provided to SSRN, Niigata Cancer Center Hospital, Chiba Cancer Center - Research Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Kawasaki Medical School, affiliation not provided to SSRN, Iwate Medical University, affiliation not provided to SSRN, affiliation not provided to SSRN, Kumamoto Kenhoku Hospital, Kyoto University - Kyoto University Hospital, affiliation not provided to SSRN and National Cancer Center Hospital
Downloads 71 (875,328)
Citation 1

Abstract:

Loading...

acral melanomapalm and solenail apparatusanti-PD-1 antibodyanti-CTLA-4 antibodynivolumabpembrolizumabipilimumab

2.

PD-1 Blockade Therapy Promotes Novel Infiltration of Tumor-Specific T-Cell Clonotypes

Number of pages: 69 Posted: 02 Mar 2021
Joji Nagasaki, Takashi Inozume, Nicolas Sax, Ryo Ariyasu, Kazuo Yamashita, Masahito Kawazu, Toshihide Ueno, Takuma Irie, Etsuko Tanji, Akiko Honobe, Takehiro Ohnuma, Mitsuru Yoshino, Takekazu Iwata, Katsushige Kawase, Keita Sasaki, Toyoyuki Hanazawa, Vitaly Kochin, Tatsuyoshi Kawamura, Hiroyuki Matsue, Masayuki Hino, Hiroyuki Mano, Yutaka Suzuki, Hiroyoshi Nishikawa and Yosuke Togashi
Okayama University, Chiba Cancer Center - Research Institute, KOTAI Biotechnologies, Inc., National Cancer Center - Division of Cancer Immunology, KOTAI Biotechnologies, Inc., National Cancer Center - Division of Cellular Signaling, National Cancer Center Research Institute (Japan), National Cancer Center - Division of Cancer Immunology, Chiba Cancer Center - Research Institute, University of Yamanashi - Department of Dermatology, Kumamoto Kenhoku Hospital, Chiba Cancer Center - Department of Thoracic Surgery, Chiba Cancer Center - Department of Thoracic Surgery, Chiba Cancer Center - Research Institute, Chiba Cancer Center - Department of Head and Neck Surgery, Chiba University - Department of Otolaryngology, Head and Neck Surgery, Nagoya University - Department of Immunology, University of Yamanashi - Department of Dermatology, Chiba University - Department of Dermatology, Osaka City University - Department of Hematology, National Cancer Center - Division of Cellular Signaling, University of Tokyo, Graduate School of Frontier Sciences, Department of Computational Biology and Medical Sciences, National Cancer Center, Japan and Chiba Cancer Center - Research Institute
Downloads 68 (899,324)

Abstract:

Loading...

tumor-specific T cell, exhausted T cell, neoantigen, tumor microenvironment, tumor-draining lymph node